Randomized crossover trial compared pharmacokinetics and sedative effects of remimazolam and midazolam in Thoroughbred horses, indicating RMZ may offer faster recovery.
Key Points
Remimazolam demonstrated a significantly shorter half-life compared to midazolam, with 0.77 hours versus 3.7 hours.
Plasma clearance for remimazolam was measured at 14.0 L/kg/h, significantly higher than midazolam's 0.45 L/kg/h.
The study involved six Thoroughbred horses receiving a single intravenous dose of either remimazolam or midazolam.
Muscle relaxation and ataxia were observed shortly after remimazolam administration, indicating quick sedative effects.